Conference Reports for NATAP

Back

EACS - 12th European AIDS Conference November 11-14, 2009 Cologne, Germany     New EACS (European AIDS Clinical Society) HIV Guidelines: HIV treatment, comorbidities (prevention and management of metabolic diseases), management and treatment of chronic hepatitis B and C coinfection in HIV+   Feedback Reports (clinical, translational) from the 11th International Workshop on Adverse Drug reactions and Co-morbidities in HIV reported at EACS 2009 Cologne - (11/20/09)   The Impact of Maraviroc on Insulin Sensitivity, Lipids and Adipokines after 2 weeks in HIV Negative Male Volunteers - (12/10/09)   Pros and Cons of Boosted PI Monotherapy - (12/10/09)   The ARTEN study: 48 week efficacy data stratified by screening viral load and CD4+ cell count - (11/30/09)   Pharmacokinetic interaction study between TMC278,an NNRTI, and the contraceptives norethindrone plus ethinylestradiol - (11/30/09)   Absorption, metabolism and excretion of TMC278, an NNRTI, after a single oral dose of 150mg in healthy male volunteers - (11/30/09)   Absence of a teratogenic potential from a novel next-generation NNRTI, TMC278 - (11/24/09)   TMC278 25mg qd has no effect on corrected QT interval in a study in HIV-negative volunteers - (11/24/09)   Framingham Risk and Lipoprotein Changes after 24 Weeks of Treatment with Abacavir/Lamivudine (ABC/3TC) and Raltegravir (RAL) in Antiretroviral-Naive HIV-1 Infected Subjects - (11/30/09)   A Pilot Study of Abacavir/Lamivudine (ABC/3TC) and Raltegravir (RAL) in Antiretroviral Naive HIV-1 Infected Subjects - (11/30/09)   Detrimental effect of current patient-reported drug holidays on long-term sub-optimal treatment out-come in advanced naive subjects initiating cART - (11/30/09)   Association of effectiveness and adherence of antiretroviral treatment - (11/30/09)   Impact of different types of adherence behaviours and of cART characteristics on plasma HIV-1 RNA detection under lower limit of quantification at real-time assay - (11/30/09)   Moving from risk factor assessment to atherosclerosis imaging to select the most appropriate patient for primary prevention: CVD algorithms underestimate risk in HIV+ - (11/30/09)   Adherence to and quality of life of a one-pill once-a-day HAART (Atripla). Results of the ADONE study - (11/24/09)   Etravirine demonstrates a favourable safety and tolerability profile versus placebo irrespective of hepatitis co-infection: Week 96 analysis from the DUET trials - (11/24/09)   The Effect of Antiretroviral Therapy Without CCR5-Antagonists on HIV-1 Tropism in the MOTIVATE Studies of Maraviroc in Treatment-Experienced Patients With R5 HIV-1 - (11/24/09)   Safety Profile of HIV-1 Patients Co-Infected With Hepatitis B or C in the Maraviroc Expanded Access Program - (11/24/09)   ASSESSMENT OF THE STEADY STATE PK PARAMETERS OF TWO EXTENDED RELEASE (XR) NEVIRAPINE (NVP) TABLETS 400 MG AND 300 MG QD COMPARED WITH IMMEDIATE RELEASE (IR) NVP TABLETS 200 MG BID IN HIV-1 INFECTED PATIENTS - THE ERVIR STUDY - (11/24/09)   Gender-Based Differences in Antiretroviral-Naïve Patients Treated With Ritonavir-Boosted Protease Inhibitors: Results From the CASTLE Study Through 96 Weeks - (11/24/09)   Viral Load Over 50 and Low CD4/CD8 Ratio Hoist MI Risk in French Cohort - Written Mark Mascolini - (11/20/09)   Risk of Cardiovascular Disease in ART-Naive People Without Heart Symptoms, Carotid Artery Ultrasonography May Be Useful - Written Mark Mascolini - (11/20/09)   Abdominal Adiposity Not Waning With Newer Antiretrovirals in France - Written Mark Mascolini - (11/20/09)   Metabolic Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analogue, in HIV-infected Patients with Excess Abdominal Fat over a Period of 52 Weeks. A Pooled Analysis of 2 Multicenter, Double- blind, Placebo-controlled Phase 3 Trials with 816 Randomized Patients - (11/20/09)   "Deep" Sequencing to Identify Treatment-Experienced Patients Who Respond to Maraviroc (MVC) - (11/20/09)   Optimization of Clinically Relevant Cutpoints for the Determination of HIV Co-Receptor Usage to Predict Maraviroc Responses in Treatment Experienced (TE) Patients Using Population V3 Genotyping - (11/20/09)   Improved Treatment Compliance with Once-Daily (QD) Compared to Twice-Daily (BID) Lopinavir/ritonavir (LPV/r) in HIV-1-Infected, Antiretroviral-Experienced Subjects - (11/20/09)   Impact of Baseline Resistance on Virologic Outcome with Once-Daily (QD) or Twice-Daily (BID) Lopinavir/ritonavir (LPV/r) through 48 Weeks of Combination Antiretroviral Therapy in Treatment-Experienced, HIV-1-Infected Subjects - (11/20/09)   Diagnosis and management of cognitive disorders during successful HIV treatment - (11/20/09)   Simplified Antiretroviral Therapy in Special Populations: Clinical Outcomes at Week 48 of Lopinavir/ritonavir (LPV/r) Tablet Dosed Once Daily (QD) or Twice Daily (BID), Administered with ≥2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in Antiretroviral-experienced Subjects, Analyzed by Gender, Age, Race, Ethnicity, and Hepatitis Co-infection Status (Study M06-802) - (11/18/09)   Etravirine demonstrates a favourable safety and tolerability profile versus placebo irrespective of hepatitis co-infection: Week 96 analysis from the DUET trials - (11/24/09)   Kaletra QD Resistance Report: Lopinavir/ritonavir (LPV/r) with Tenofovir DF (TDF) and Emtricitabine (FTC) in Antiretroviral (ARV)-naïve Subjects - (11/18/09)   Etravirine demonstrates a favourable safety and tolerability profile: pooled 96-week results from the Phase III DUET trials - (11/18/09)   Safety and pharmacokinetics of etravirine in pregnant HIV-infected women - (11/18/09)   Tesamorelin Health-Related Quality of Life in HIV+ regarding belly and weight image - (11/18/09)   MIs, Cocaine/IVDUs French Database - (11/17/09)   S/GSK1349572 Integrase Inhibitor Resistance Profile - (11/17/09)   Potent Antiviral Activity of GSK Integrase S/GSK1349572 - (11/17/09)   A Phase II, open-label trial in treatment-naïve, HIV-1-infected patients who received DRV/r as induction monotherapy - (11/17/09)   Twice Daily Darunavir to Replace Dual Boosted Protease Inhibitors in Virologically Suppressed Patients - (11/17/09)   Simplification with fixed-dose tenofovir-emtricitabine or abacavir-lamivudine in adults with HIV infection: meta-analysis of two randomised, non-inferiority trials BICOMBO and STEAL - (11/17/09)   Fatty Liver in HIV & HCV - (11/17/09)   A Phase II, open-label trial in treatment-naïve, HIV-1-infected patients who received DRV/r as induction monotherapy - (11/15/09)   Darunavir Maintenance Monotherapy - (11/15/09)   Comparison of lipid profile with nevirapine versus atazanavir/ritonavir, both combined with tenofovir DF and emtricitabine (TDF/FTC), in treatment-naïve HIV-1 infected patients: ARTEN Study Week 48 results - (11/15/09)   Body Composition Changes in Treatment-Naive Patients Treated with Boosted Protease Inhibitors Plus Tenofovir/Emtricitabine: Results From the CASTLE Study Through 96 Weeks - (11/15/09)   Assessment of Safety and Efficacy of Abacavir/Lamivudine and Tenofovir/Emtricitabine in Treatment-Naïve HIV-1 Infected Subjects ASSERT: 48-Week Result - (11/15/09)   Once-Daily Dosing Ups Risk of Stopping Antiretrovirals in Single-Clinic Study - written by Mark Mascolini - (11/15/09)   Lower Intracellular Carbovir (Abacavir) Levels With Darunavir/Ritonavir - written by Mark Mascolini - (11/15/09)   Darunavir Troughs Lower With Raltegravir in Cross-Sectional Study - written by Mark Mascolini - (11/15/09)   More Evidence of Low Vitamin D in People Taking Antiretrovirals - written by Mark Mascolini - (11/15/09)   Study of Once-Daily Boosted Darunavir Monotherapy as First-Line Therapy Had Difficulty - written by Mark Mascolini - (11/15/09)   Multicohort Study Confirms Continuing Hodgkin Lymphoma Risk With HAART - written by Mark Mascolini - (11/15/09)   Good 4-Year HIV Response in People Over 60, But High Cancer and Heart Disease Rates - written by Mark Mascolini - (11/15/09)   Later Year and Age Over 50 Tied to Better Response After Triple-Class Failure - written by Mark Mascolini - (11/15/09)   Hodgkin Lymphoma, Liver Cancer, Anal Cancer More Common With HIV - written by Mark Mascolini - (11/13/09)   Mortality High With Non-AIDS Cancers in EuroSIDA Despite HAART - written by Mark Mascolini - (11/13/09)   More Than Half in HIV Patient Series Carry High-Risk Human Papillomavirus - written by Mark Mascolini - (11/13/09)   Rough Group Sex--Not Just Anal Sex--May Explain HCV Epidemic in HIV+ Gays - written by Mark Mascolini - (11/13/09)   MONET Paints Noninferiority Picture With Darunavir/Ritonavir Monotherapy - written by Mark Mascolini - (11/13/09)   Twice-Daily Darunavir/Ritonavir to Replace Double-Boosted PIs - written by Mark Mascolini - (11/13/09)